ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0293

Assessment of Skin Cancer Risk in Autoimmune Diseases: A Multivariate Analysis Using a National Inpatient Database

Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, Autoinflammatory diseases, risk assessment, skin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Autoimmune diseases are known to be associated with an increased risk of many types of cancers. This study investigates the association between different types of skin cancers and certain autoimmune diseases.

Methods: We conducted a retrospective study using the National Inpatient Sample (NIS) database, analyzing data from patients aged 18 and above admitted between 2016 and 2019. The diseases studied were identified using the International Classification of Diseases, Tenth Revision (ICD-10) codes. We applied multivariate logistic regression models to determine the adjusted odds ratios (AORs) for skin cancers associated with various autoimmune conditions. Adjustments were made for potential confounders, including age, sex, race, smoking status, history of immunosuppression, organ transplantation, HIV infection, and the presence of specific autoimmune diseases.

Results: The study revealed significant associations between certain autoimmune conditions and skin cancers compared to patients without an autoimmune disease. Patients with rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis were found to have increased odds of developing cutaneous squamous cell carcinoma, with adjusted odds ratios (AOR) of 1.24 (95% Confidence Interval [CI] 1.05-1.47, P=0.01), 1.76 (95% CI 1.22-2.54, P=0.002), and 1.96 (95% CI 1.01-3.78, P=0.04), respectively. In contrast, no significant association was found for melanoma and basal cell carcinoma.

Patients with dermatomyositis had significantly increased odds of developing melanoma (AOR 2.44 [95% CI 1.16-5.13], P=0.018). Meanwhile, their odds of developing cutaneous squamous cell carcinoma and basal cell carcinoma were not statistically significant.

Results are summarized in Table 1.

Conclusion: This retrospective study demonstrates an association of skin cancers with certain autoimmune conditions. Notably, there is an elevated risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis, as well as an increased risk of melanoma in patients with dermatomyositis. These results highlight the need for regular dermatologic screenings for individuals with autoimmune diseases.

Supporting image 1


Disclosures: S. Rabah: None; X. Kang: None.

To cite this abstract in AMA style:

Rabah S, Kang X. Assessment of Skin Cancer Risk in Autoimmune Diseases: A Multivariate Analysis Using a National Inpatient Database [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/assessment-of-skin-cancer-risk-in-autoimmune-diseases-a-multivariate-analysis-using-a-national-inpatient-database/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-skin-cancer-risk-in-autoimmune-diseases-a-multivariate-analysis-using-a-national-inpatient-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology